1. Kane Biotech Restarts North American Commercial Operations (KNE:TSX‑V)
Kane Biotech has resumed commercial activity in both the U.S. and Canada for its revyve antimicrobial wound‑care line, supported by new senior commercial appointments in each market. The restart positions the company for renewed revenue traction in 2026 and places fresh attention on Canadian small‑cap biotech execution as cross‑border distribution ramps.
2. Eli Lilly’s Multi‑Billion‑Dollar Deal Spree Reshapes North American Biotech (LLY:NYSE)
Eli Lilly’s aggressive transaction activity—highlighted by its acquisition of Orna Therapeutics and a major strategic collaboration with Innovent—continues to influence sector sentiment as 2026 unfolds. The company’s expansion into autoimmune disease and in‑vivo cell therapy sets competitive pressure across North American pipelines, with Canadian developers in adjacent modalities likely to see increased comparative scrutiny.
3. Biotech IPO Window Shows Early Signs of Reopening (No Symbol)
North American equity markets are showing renewed receptivity to biotech listings after a prolonged drought, with recent offerings signaling tentative momentum heading into 2026. While still fragile, the shift is drawing attention from Canadian issuers evaluating timing for potential capital‑markets re‑entry, particularly those with late‑stage assets or near‑term catalysts.
